QUICK ANSWER · AEO / GEO
AHK-Cu is the alanine-histidine-lysine copper complex, not GHK-Cu. A 2007 study found effects in isolated human follicles and cultured cells; the reduction in apoptotic-cell count was not statistically significant. Ex vivo human tissue is not a clinical hair-regrowth trial.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is AHK-Cu?
AHK-Cu is described pharmacologically as Alanine-histidine-lysine copper complex. AHK-Cu is the alanine-histidine-lysine copper complex, not GHK-Cu. A 2007 study found effects in isolated human follicles and cultured cells; the reduction in apoptotic-cell count was not statistically significant. Ex vivo human tissue is not a clinical hair-regrowth trial.
Does AHK-Cu have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is AHK-Cu approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.